Precision Management of Gastrointestinal Tumor-Associated Osteoporosis Driven by Cutting-Edge Technologies: Current Status, Challenges, and Future Prospects

The review defines GTO as secondary osteoporosis in patients with gastrointestinal tumors caused by tumor-derived factors, chemotherapy, surgery, or malabsorption, and frames it as an underrecognized but clinically significant complication affecting skeletal health, treatment adherence, quality of life, and long-term prognosis. Rather than treating osteoporosis as a generic age-related condition, it positions GTO as a distinct complication within the gastrointestinal cancer care pathway and sets out a multifactorial pathogenic framework. A review-level definition and synthesis; the text offers qualitative statements such as 'underrecognized but clinically significant complication' without specific epidemiological figures.

The review synthesizes a multifactorial pathogenesis for GTO involving metabolic imbalance in the tumor microenvironment, antitumor therapy-related bone toxicity, and nutrient malabsorption from gastrointestinal dysfunction, which together raise the risk of skeletal-related events and worsen clinical outcomes. It integrates tumor microenvironment, treatment toxicity, and intestinal absorption into a single mechanistic frame instead of discussing them separately. A narrative mechanistic synthesis; no specific pathway molecules or effect sizes are reported in the text.

The review outlines three technology directions for GTO precision management: AI-assisted early screening and risk prediction, nano-enabled targeted bone protection, and multiomics-based mechanistic exploration of the tumor-bone-gut axis. It places AI, nanotargeted delivery, and multiomics side by side as pillars of GTO precision management, mapping them from screening and prediction to protective intervention and mechanistic dissection. An inductive summary of application directions; no specific model performance, delivery efficiency, or omics findings are reported.

The review identifies major barriers to clinical translation, including limited AI generalizability, nanomedicine safety and manufacturing challenges, difficulties in multidimensional data integration and standardization, imperfect multidisciplinary collaboration, and ethical concerns. It presents translation barriers across technology, data, organizational, and ethical layers rather than attributing them to a single technical bottleneck. A qualitative barrier list; the text provides no quantitative assessment or comparative ranking of these barriers.

This article is positioned as a review framework of the technological landscape and translational pathways for GTO precision management, intended for clinical researchers, translational teams, and technology developers concerned with skeletal complications in gastrointestinal cancer patients, to help identify methodological gaps and standardization needs across AI screening and prediction, nano-enabled targeted bone protection, and multiomics mechanistic research. Its conclusions are aimed at research planning and agenda setting rather than directly guiding a specific clinical decision.

Readers would still want to know: what data sources, populations, and validation approaches underlie AI-assisted screening and risk prediction; what concrete progress exists on the safety, manufacturing, and regulatory pathways of nano-enabled targeted bone protection; what actionable schemes exist for multidimensional data integration and standardization; and how multidisciplinary collaboration and ethical frameworks would be implemented. Because the currently loaded content is an abstract-level fast parse lacking figures and specific data, these questions cannot be further confirmed within this text and remain open questions requiring the original article or subsequent research.